Evaluation of the Effectiveness of Eliquis (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries

Trial Profile

Evaluation of the Effectiveness of Eliquis (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Apixaban (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 28 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 16 Oct 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top